FDA approves new treatment for advanced basal cell carcinoma (skin cancer) -7/27/15

  • By Norma Cataldo
  • 28 Jul, 2015

Odomzo is a pill taken once a day.

FDA Approval
The U.S. Food and Drug Administration approved Odomzo (sonidegib) to treat patients with locally advanced basal cell carcinoma that has recurred following surgery or radiation therapy, or who are not candidates for surgery or radiation therapy. Odomzo is a pill taken once a day.

It works by inhibiting a molecular pathway, called the Hedgehog pathway, which is active in basal cell cancers. By suppressing this pathway, Odomzo may stop or reduce the growth of cancerous lesions.

“Our increasing understanding of molecular pathways involved in cancer has led to approvals of many oncology drugs in difficult–to–treat diseases for which few therapeutic options previously existed,” said Richard Pazdur, M.D., director of the Office of Hematology and Oncology Products in the FDA’s Center for Drug Evaluation and Research. “Thanks to a better understanding of the Hedgehog pathway, the FDA has now approved two drugs for the treatment of basal cell carcinoma just in the last three years.” In 2012, Erivedge (vismodegib) was the first drug approved to treat locally advanced and metastatic basal cell carcinoma.
By Norma Cataldo October 7, 2017
What can you do to keep your skin from aging? Learn about treatment options that prevents and prolongs a youthful skin.
By Norma Cataldo August 10, 2017
Learn about restoring Womans Intimate Areas with the Exilis Ultra laser treatment for vagina rejuvenation. Improves visual appearance and sexual intimacy.
By Norma Cataldo August 1, 2017
#Ultrashape in Boston and Rhode Island - Best, Permanent Laser Fat Removal vs Coolscupting and Why
More Posts